LOS ANGELES, Nov. 26, 2024 (GLOBE NEWSWIRE) — via IBN – Kairos Pharma Ltd. (NYSE American: KAPA), a clinical-stage biopharmaceutical company focused on advancing innovative oncology therapeutics, has selected IBN, a multifaceted financial news and publishing company for private and public entities, to spearhead its corporate communications efforts.
Kairos Pharma’s development pipeline targets drug resistance and immune suppression, two critical barriers to effective cancer treatment. The company’s flagship program, ENV105, is designed to address resistance in anti-androgen and EGFR-based therapies by targeting CD105, a protein that cancer cells produce to evade treatment. This innovative approach has the potential to revitalize existing cancer drugs and deliver lasting benefits for patients. ENV105 is currently in Phase 2 trial for prostate cancer and Phase 1 trial for lung cancer, addressing significant unmet medical needs.
Beyond ENV105, Kairos is advancing a broad pipeline of novel therapies designed to enhance the immune system’s ability to combat cancer. These include programs targeting immune suppression and novel treatments for autoimmune diseases. By leveraging strategic relationships, including one with Cedars-Sinai Medical Center, Kairos is able to accelerate clinical development while maintaining efficiency and quality.
With a robust pipeline, experienced leadership, and an intellectual property portfolio extending to 2040, Kairos Pharma is uniquely positioned to address widespread challenges in oncology, including the $11.3 billion prostate cancer market, the $14 billion lung cancer market, and the $118 billion immunotherapy sector.
As part of the Client Partner relationship, IBN will leverage its investor-focused distribution network, which includes over 5,000 key syndication outlets, various newsletters, social media channels, and wire services via InvestorWire, along with blogs and other outreach tools, to generate greater awareness for Kairos Pharma.
With over 18 years of experience assisting over 500 client partners and a sizable family of 70+ trusted brands, IBN has amassed a collective audience that includes millions of social media followers. This positions IBN to provide Kairos Pharma the solutions needed to reach a wide audience of investors, journalists, and the general public.
To learn more about Kairos Pharma, please visit the company’s corporate newsroom at https://IBN.fm/KAPA
About Kairos Pharma Ltd.
Based in Los Angeles, California, Kairos Pharma Ltd. is at the forefront of oncology therapeutics, utilizing structural biology to overcome drug resistance and immune suppression in cancer. Its lead candidate, ENV105, is an antibody that targets CD105—a protein identified as a key driver of resistance to various cancer treatments. Elevation of CD105 in response to standard therapy results in resistance and disease relapse. ENV105 aims to reverse drug resistance by targeting CD105 and restore the effectiveness of standard therapies across multiple cancer types. Currently, ENV105 is in a Phase 2 clinical trial for castrate resistant prostate cancer and a Phase 1 trial for lung cancer, addressing significant unmet medical needs.
For more information, visit the company’s website at www.KairosPharma.com
About IBN
IBN consists of financial brands introduced to the investment public over the course of 18+ years. With IBN, we have amassed a collective audience of millions of social media followers. These distinctive investor brands aim to fulfill the unique needs of a growing base of client-partners. IBN will continue to expand our branded network of highly influential properties, leveraging the knowledge and energy of specialized teams of experts to serve our increasingly diversified list of clients.
Through our Dynamic Brand Portfolio (DBP), IBN provides: (1) access to a network of wire solutions via InvestorWire to reach all target markets, industries and demographics in the most effective manner possible; (2) article and editorial syndication to 5,000+ news outlets; (3) Press Release Enhancement to ensure maximum impact; (4) full-scale distribution to a growing social media audience; (5) a full array of corporate communications solutions; and (6) total news coverage solutions.
For more information, please visit https://www.InvestorBrandNetwork.com
Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: https://IBN.fm/Disclaimer
Forward-Looking Statements
This release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended and Section 21E of the Securities Exchange Act of 1934, as amended. All forward-looking statements are inherently uncertain as they are based on current expectations and assumptions concerning future events or future performance of the company. Readers are cautioned not to place undue reliance on these forward-looking statements, which are only predictions and speak only as of the date hereof. In evaluating such statements, prospective investors should review carefully various risks and uncertainties identified in this release and matters set in the company’s SEC filings. These risks and uncertainties could cause the company’s actual results to differ materially from those indicated in the forward-looking statements.
Corporate Communications
IBN
Los Angeles, California
www.InvestorBrandNetwork.com
310.299.1717 Office
[email protected]
